Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - Cardiff Oncology, Inc.v351094_ex99-1.htm

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 29, 2013

 

Trovagene, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   27-2004382
(State or other jurisdiction   IRS Employer
of incorporation or organization)   Identification No.)

 

11055 Flintkote Avenue, Suite B

San Diego, CA 92121

(Address of principal executive offices)

 

Registrant’s telephone number, including area code: (858) 952-7570

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o         Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o         Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o         Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o         Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

 

Item 8.01                    Other Events.

 

On July 29, 2013, Trovagene, Inc. (the “Company”) issued a press release announcing Trovagene has adopted RainDance’s RainDropTM Digital PCR System for research and development, and for eventual use in the Trovagene CLIA laboratory. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information disclosed under this Item 8.01, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as expressly set forth in such filing.

 

Item 9.01.               Financial Statements and Exhibits

 

(d) Exhibits.

 

99.1 Press Release dated July 29, 2013

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated:         July 29, 2013

 

  TROVAGENE, INC.
   
   
  By: /s/ Antonius Schuh
    Antonius Schuh
    Chief Executive Officer